SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged at the end of 2019 and by mid-June 2020 the virus had spread to at least 215 countries, caused more than 8 000 000 confirmed infections and over 450 000 deaths, and overwhelmed healthcare systems worldwide. Like severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 and caused a similar disease, SARS-CoV-2 is a betacoronavirus. Both viruses use human angiotensin-converting enzyme 2 (hACE2) as a receptor to enter cells. However, the SARS-CoV-2 spike (S) glycoprotein has a novel insertion that generates a putative furin cleavage signal and this has been postulated to expand the host range. Two low-passage (P) strains of SARS-CoV-2 (Wash1 : P4 and Munich : P1) were cultured twice in Vero E6 cells and characterized virologically. Sanger and MinION sequencing demonstrated significant deletions in the furin cleavage signal of Wash1 : P6 and minor variants in the Munich : P3 strain. Cleavage of the S glycoprotein in SARS-CoV-2-infected Vero E6 cell lysates was inefficient even when an intact furin cleavage signal was present. Indirect immunofluorescence demonstrated that the S glycoprotein reached the cell surface. Since the S protein is a major antigenic target for the development of neutralizing antibodies, we investigated the development of neutralizing antibody titres in serial serum samples obtained from COVID-19 human patients. These were comparable regardless of the presence of an intact or deleted furin cleavage signal. These studies illustrate the need to characterize virus stocks meticulously prior to performing either in vitro or in vivo pathogenesis studies.

• Authors: William B Klimstra, Natasha L Tilston-Lunel, Sham Nambulli, James Boslett, Cynthia M McMillen, Theron Gilliland, Matthew D Dunn, Chengun Sun, Sarah E Wheeler, Alan Wells, Amy L Hartman, Anita K McElroy, Douglas S Reed, Linda J Rennick, W Paul Duprex
• Journal: The Journal of general virology (J Gen Virol) Vol. 101 Issue 11 Pg. 1156-1169 (11 2020) ISSN: 1465-2099 [Electronic] England
• PMID: 32821033 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antibodies, Neutralizing
• Immunoglobulin A
• Immunoglobulin G
• RNA, Viral
• Furin

Topics

• Adaptation, Physiological
• Animals
• Antibodies, Neutralizing (immunology)
• COVID-19 (epidemiology, immunology, metabolism, virology)
• Chlorocebus aethiops
• Furin (immunology, metabolism)
• Genetic Variation
• Hospitalization
• Host-Pathogen Interactions (immunology)
• Humans
• Immunoglobulin A (immunology)
• Immunoglobulin G (immunology)
• Neutralization Tests
• Proteolysis
• RNA, Viral
• SARS-CoV-2 (physiology)
• Sequence Analysis, RNA
• Vero Cells
• Viral Load
• Virus Replication